Sangui BioTech International Inc.: Revenues Attain USD 133,000 in Financial Year 2014

For its financial year 2014 (ended June 30, 2014) Sangui BioTech International, Inc. reports revenues from product sales and royalties in the amount of USD133,470 USD after USD105,487 in the previous financial year. This increase is primarily attributable to royalties on sales of the Granulox wound dressing, marketing and sales of which are out-licensed to SastoMed GmbH, a joint venture company in which Sangui holds a stake of 25%. Revenues in the fourth quarter of the 2014 financial year came in at USD43,729 USD (Q4/2013: USD24,056). Granulox is the first dressing to significantly improve oxygen supply to wounds with poor blood supply and thereby decisively accelerates wound healing.

Help employers find you! Check out all the jobs and post your resume.